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Abstract: Low-molecular-weight heparins (LMWHs) have been widely studied in pivotal 
clinical trials or in several meta-analyses. However, the safety and optimal use of LMWHs in 
high-risk patients such as the very elderly remains uncertain since these patients are usually 
excluded from clinical trials. In terms of LMWHs in the elderly, the main concerns are renal 
failure and the risk of accumulation. A clinical approach consisting of a LMWH dose reduction 
in the elderly should be considered with great caution in terms of efficacy, since it has been 
tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in 
patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa activity 
levels should be used and so far, no anti-Xa activity-based guidelines have been issued. More-
over, no data support any laboratory monitoring in elderly patients treated with prophylactic 
dose LMWHs.
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The number of elderly patients who require anticoagulant therapy is rising steadily 
as the aging of the population is causing increases in the prevalence of venous and 
  arterial thromboembolism. Due to the higher risk of bleeding, managing anticoagulants 
in these frail patients may be challenging. Among anticoagulants used to prevent 
or treat thromboembolism events, low-molecular weight heparins (LMWHs) have 
been widely studied in pivotal clinical trials or in several meta-analyses. However, 
despite their wide development and use, the safety and optimal use of LMWHs in 
high-risk patients such as the very elderly, remain uncertain since these patients are 
usually excluded from clinical trials. So far, only one study has been conducted in 
elderly patients with moderate to severe renal impairment: the “Innohep® in Renal 
Insufficiency Study” (IRIS). Unfortunately, this trial was prematurely stopped thus 
the results are unconclusive.1
In a recent issue of this Journal, Robert-Ebadi et al thoroughly reviewed the 
risk/benefit ratio of the use of anticoagulation in elderly patients and considered 
  different approaches to improve safety in this population.2 One concern raised in this 
review is the increased risk of accumulation and bleeding in patients with impaired renal 
  function receiving LMWHs, since LMWHs are mainly excreted by the kidney.
In patients with severe renal impairment (creatinine clearance 30 mL/min) who 
require therapeutic anticoagulation, Robert-Ebadi et al suggest using unfractionated 
heparin instead of LMWHs. If LMWH is used in these patients, they suggest ‘LWMH 
with dose reduction (1/2 dose).’ These recommendations are in agreement with those Clinical Interventions in Aging 2010:5 120
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of the Eighth American College of Chest Physicians (ACCP) 
Consensus Conference on Antithrombotic and Thrombolytic 
Therapy.3 It is noteworthy that the ACCP recommendations 
on this topic are weak with a low quality of evidence (grade 
2C) and are mostly based on studies with enoxaparin.3 So 
far, the efficacy and safety of LMWHs used at reduced initial 
dosages have not been evaluated in the treatment of acute 
venous thromboembolism (VTE).4 A dose-adjustment pro-
posal according to renal function has only been investigated in 
patients with acute coronary syndrome receiving enoxaparin: 
the authors of the study observed that a dose reduction lead-
ing to low anti-Xa levels (0.5 U/mL) may increase the risk 
of mortality and recurrent ischemic events.5
A dose reduction is also suggested by Robert-Ebadi 
et al in patients receiving prophylactic doses of LMWHs in 
medical setting. The results of the two main clinical trials 
assessing the use of enoxaparin (MEDENOX) and dalteparin 
(PREVENT) for the prevention of venous thromboembolism 
in acutely ill medical patients do not support such an 
option.6,7 Indeed, in the MEDENOX study, the daily 40 mg 
enoxaparin dosage was particularly effective in the group 
of patients older than 80 years (the risk reduction of VTE 
was 87% in patients 80 years and older as compared with 
63% in the general study population), while the daily 20 mg 
dosage was similar to placebo.6 Similarly, in the PREVENT 
study, the relative treatment effect of dalteparin was not 
attenuated when adjusted for age with a 48% reduction of 
VTE events in patients aged 75 years and older treated with 
dalteparin compared with patients receiving placebo, without 
an increase in major hemorrages.8 Thus, due to the lack of 
clinical evidence, we think that the decision to use reduced 
therapeutic or prophylactic dosages should be considered 
with great caution since it could be beneficial in terms of 
safety but deleterious in terms of efficacy.
To date it has not been demonstrated that plasma 
anti-Xa activity levels correlate with clinical outcomes. 
Dose finding studies with LMWHs used at curative doses 
have demonstrated that increasing the dose was associated 
with higher anti-Xa activity levels and an increased risk of 
major bleeding.10 Monitoring of anti-Xa activity in patient 
treated with therapeutic LMWH dose may be recommended 
to detect an overdosage and/or accumulation in patients 
with renal impairment.3 In their review, Robert-Ebadi et al 
  suggest considering anti-Xa monitoring in elderly patients 
treated with therapeutic doses of LMWH and to use the 
target ranges of 0.6–1 IU/mL for twice-daily LMWH and 
1–2 IU/mL for once-daily LMWHs. These ranges are 
those cited by Kearon et al in the Antithrombotic therapy 
for venous thromboembolism disease chapter of the ACCP 
guidelines.9 The use of these conservative target ranges may 
lead to a misinterpretation of the anti-Xa activity. Indeed, 
due to a better understanding of the pharmacodynamic profile 
of each LMWH preparation, more accurate target levels for 
anti-Xa activity have been published, especially by Hirsh et al 
in the Parenteral anticoagulants chapter of the same issue 
of the ACCP guidelines: 1.0 with enoxaparin; 0.87 IU/mL 
with tinzaparin; 1.34 IU/mL with once-daily and 1.01 with 
twice-daily nadroparin; 1.05 IU/mL with once daily and 
0.59 IU/mL with twice-daily dalteparin.3,10 Moreover, it is 
noteworthy that so far, no dose adjustment guidelines based 
on anti-Xa activity are available.
Finally, in patients with severe renal impairment treated 
with prophylactic doses of LMWHs, Robert-Ebadi et al 
  suggest to monitor anti-Xa activity to detect an accumulation 
based on Mahé et al study.11 However in the latter study, the 
authors came to the conclusion that ‘the results do not support 
laboratory monitoring in patients treated with prophylactic 
doses of enoxaparin, even older patients with impaired renal 
function and/or low body-weight.’ Indeed, they showed that 
in 125 acutely ill medical inpatients (mean age 87 years) 
receiving daily 4000 IU of enoxaparin up to 10 days, the mean 
anti-Xa activity value was slightly but significantly higher dur-
ing the course than at the beginning of therapy. The difference 
in mean anti-Xa activity levels between patients with versus 
those without severe renal impairment was only of 0.11 IU/mL 
and the mean peak anti-Xa value in patients with severe renal 
impairment was of 0.72 IU/mL, ie, levels of anti-Xa activity 
not clearly associated with an increased risk of bleeding.11
In terms of LMWHs in the elderly, renal failure and the 
risk of accumulation is the main concern. However, other 
situations such as extreme body weight are also of concern. 
For thromboprophylaxis, a strong negative correlation was 
found between total body weight and anti-Xa levels in 
elderly inpatients treated with fixed-dose enoxaparin11 and in 
nonelderly obese patients treated with fixed-dose enoxaparin 
and nadroparin.3 Due to the paucity of data, no validated 
recommendations in these situations are available.
In conclusion, the approach consisting of a LMWH dose 
reduction in the elderly should be considered with great 
  caution in terms of efficacy, since it has been tested neither in 
the treatment of VTE nor in VTE prophylaxis. If monitoring 
is considered in patients receiving therapeutic dose LMWHs, 
appropriate target ranges for peak anti-Xa levels should be 
used and so far, no anti-Xa based guidelines have been issued. 
Finally, no data support any laboratory monitoring in elderly 
patients treated with prophylactic doses LMWHs. Random-Clinical Interventions in Aging
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ized clinical trials specifically devoted to elderly patients are 
necessary to better evaluate the risk/benefit ratio of LMWHs 
in this population and to issue guidelines in this population.
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